Witnessing the stock’s movement on the chart, on N/A, Kymera Therapeutics Inc (NASDAQ: KYMR) had a quiet start as it plunged -3.43% to $54.66, before settling in for the price of $56.6 at the close. Taking a more long-term approach, KYMR posted a 52-week range of $19.44-$58.93.
The Healthcare sector firm’s twelve-monthly sales growth has been -26.36% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was -26.36%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -12.08%. This publicly-traded company’s shares outstanding now amounts to $70.56 million, simultaneously with a float of $59.07 million. The organization now has a market capitalization sitting at $3.91 billion. At the time of writing, stock’s 50-day Moving Average stood at $45.33, while the 200-day Moving Average is $38.97.
Kymera Therapeutics Inc (KYMR) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Kymera Therapeutics Inc’s current insider ownership accounts for 17.38%, in contrast to 94.96% institutional ownership. According to the most recent insider trade that took place on Sep 17 ’25, this organization’s Chief Financial Officer sold 79,220 shares at the rate of 50.00, making the entire transaction reach 3,961,380 in total value, affecting insider ownership by 227,409.
Kymera Therapeutics Inc (KYMR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
Kymera Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -12.08% and is forecasted to reach -4.00 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -12.93% through the next 5 years, which can be compared against the -26.36% growth it accomplished over the previous five years trading on the market.
Kymera Therapeutics Inc (NASDAQ: KYMR) Trading Performance Indicators
Let’s observe the current performance indicators for Kymera Therapeutics Inc (KYMR). It’s Quick Ratio in the last reported quarter now stands at 8.32. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 87.41.
In the same vein, KYMR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.48, a figure that is expected to reach -0.76 in the next quarter, and analysts are predicting that it will be -4.00 at the market close of one year from today.
Technical Analysis of Kymera Therapeutics Inc (KYMR)
Going through the that latest performance of [Kymera Therapeutics Inc, KYMR]. Its last 5-days volume of 1.13 million indicated improvement to the volume of 0.76 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 79.76% While, its Average True Range was 63.00.
Raw Stochastic average of Kymera Therapeutics Inc (KYMR) in the period of the previous 100 days is set at 86.17%, which indicates a major rise in contrast to 67.37% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 2.39 that was higher than 2.01 volatility it exhibited in the past 100-days period.
